With that in mind, let's consider two stocks down 17% and 36%, respectively, this year that are worth investing in right now: ...

The FDA has started a review of MSD's respiratory syncytial virus (RSV) antibody clesrovimab, with a verdict due in the middle of next year. If approved by the 10th June action date, clesrovimab ...